Nolvadex or tamoxifen citrate is an Antiestrogen non-steroidal, admired by the members of the medical community to treat patients with breast cancer, because it has the ability to compete with estrogen for binding sites in target tissues.
Established (DMBA) is also effective for the regression of tumors dimethylbenzanthracene already, Nolvadex tends to have its anti-tumor properties by binding to the estrogen receptor. He is considered to be an important part of a treatment therapy of metastatic breast cancer in women and men. This wonder drug can be an effective alternative to ovariectomy or ovarian irradiation in premenopausal women with metastatic breast cancer.
Nolvadex is chemically derived from triphenylethylene trans isomer and has the chemical name (z) 2-[4-(1,2-diphenyl-1-butenyl) phenoxy] - N, N-dimethylethanamine 2 hydroxy-1-propanetricarboxylate (1: 1).
The recommended dose of Nolvadex is 20-40 mg per day or by Medical; Council Nolvadex dose can be taken with or without meals. Tablets of Nolvadex which should be swallowed with water or a non-alcoholic liquid. This medication should not be used without a qualified doctor and not recommended for patients with known hypersensitivity to the drug or any of its ingredients. It is also important to note that the Nolvadex is not a medication that you can take if you are a pregnant woman or expected that you can lead to harm to the fetus.
When you use contrary to medical advice, Nolvadex can cause side effects such as vaginal discharge, pelvic pain, difficulty breathing, swelling of the legs, stroke, jaundice and liver problems.
However, Nolvadex may be a drug to save lives, but only when used in accordance with instructions from a qualified physician.
Jack Mahlot is a nutritionist by profession and has been contributing widely as prolific columnist in many magazines health and author of sites. The beauty of the writing of Jack lies in its ability to connect with their readers almost instantly, making it easy for them to ingest them in their daily programmes.
No comments:
Post a Comment